HLS Therapeutics (TSE:HLS) Sets New 12-Month Low – Here’s What Happened

HLS Therapeutics Inc. (TSE:HLS) shares reached a new 52-week low on Wednesday . The stock traded as low as C$3.71 and last traded at C$3.75, with a volume of 37404 shares traded. The stock had previously closed at C$3.90.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on HLS shares. Raymond James Financial raised shares of HLS Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from C$7.00 to C$8.00 in a report on Friday, August 14th. Canaccord Genuity Group raised HLS Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Strong Buy” and an average target price of C$8.00.

HLS Therapeutics Stock Performance

The company has a debt-to-equity ratio of 75.86, a quick ratio of 1.01 and a current ratio of 1.05. The stock’s fifty day moving average is C$4.20 and its two-hundred day moving average is C$4.40. The firm has a market cap of C$116.97 million, a price-to-earnings ratio of -13.85 and a beta of -0.18.

HLS Therapeutics (TSE:HLS) last posted its earnings results on Wednesday, August 12th. The company reported C($0.03) earnings per share (EPS) for the quarter. HLS Therapeutics had a negative net margin of 15.26% and a negative return on equity of 14.39%. The firm had revenue of C$14.67 million for the quarter. During the same period last year, the firm earned ($0.09) earnings per share. On average, analysts expect that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue.